Perrigo Company PLC’s planned acquisition of French firm HRA Pharma will not only bring additional products and markets, but also enhance the private label OTC giant’s outlook for being first in the US to introduce additional nonprescription ingredients.
HRA, officially identified in France as Hera SAS, brings needed expertise in OTC switches to Perrigo, which is regularly is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?